Background: Recent investigations have suggested the clinical efficacy of granulocyte colony-stimulating factor (G-CSF) infusion alone or in combination with a single dose delivery of peripheral blood stem cells (PBSC) infusion in patients with myocardial infarction (MI) and congestive heart failure (HF). The current study tested the feasibility and effect of repeated intracoronary infusions PBSC and the mobilization of G-CSF in patients with refractory HF after MI.
ecent studies have suggested that granulocyte-colony stimulating factor (G-CSF) used alone and/or in a combination with intracoronary peripheral blood stem cells (PBSC) delivery might alleviate cardiac remodeling, improve heart function and myocardium perfusion in postmyocardial infarction (MI) models. 1-5 Some clinical studies, however, have generated inadequate evidence showing the efficacy of G-CSF with and without stem cell infusions in post-MI patients. 6-9 A correlationship between the number of cells infused and clinical outcome has been proposed recently. 10 Repeated skeletal myoblast implantation reportedly improves left ventricular (LV) function potentially as a more effective cell delivery method. 11 Stem cell mobilization by repeated administration of G-CSF together with a single intracoronary stem cell infusion might reduce angina frequency and increase exercise tolerance, but make no change in cardiac perfusion and function. 12 
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In this study, we tested the hypothesis that repeated delivery of PBSC might result in better outcome and significant clinical improvement in cardiac function. We evaluated the feasibility and efficacy of repeated intracoronary infusion of PBSC following by mobilization of G-CSF in patients with refractory heart failure (HF) after recent massive MI.
Methods

Study Protocol
The current phase-I study was a prospective, open-labeled and controlled trial, designed to investigate the safety, feasibility, and effectiveness of repeated intracoronary infusions of PBSC and the mobilization of G-CSF in patients with refractory HF after a recent large MI. Outcomes were determined in a blinded fashion. The protocol was conducted in accordance with the Helsinki declaration and approved by the ethics committee of the Northern People's Hospital. A written informed consent was obtained from the patients after having explained the procedure and its risks. Under standard medical and primary percutaneous coronary intervention (PCI) therapy, those patients with refractory HF after a recent large MI were enrolled. To induce proliferation and mobilization of PBSC, we initiated pharmacological stimulation with G-CSF for the cell therapy group. After stimulating the presence of PBSC in the peripheral blood, we performed cell apheresis and the first intracoronary PBSC infusion. The PBSC suspension was injected into the infarct-related region through a balloon catheter. The patients in the repeated infusion group were scheduled to receive the second intracoronary PBSC infusion 6 months later. The PBSC dose was similar for each patient and each timepoint. Patients were followed up to 12 months after the first PBSC transplantation. Change in LV ejection fraction (LVEF) measured by M-mode echocardiography was the primary endpoint. The second endpoint was the change in LV end-diastolic diameter (LVEDd), LV shortening fraction (LVFS), the myocardial perfusion, exercise capacity on a 6-min walking test and New York Heart Association (NYHA) class. All the analyses were performed Comparison of quantitative CD34+ cells from peripheral blood between cell therapy groups. CD34+ cell populations rose in cell therapy groups (P<0.01), but there was no significant difference between cell therapy groups (P>0.05). Group C, control group; Group S, single infusion group; Group R, repeated infusion group. G-CSF, granulocyte colony-stimulating factor. Repeated Infusion of PBSC With G-CSF in HF by experienced operators who were blinded to the study protocol. Echocardiography was performed at baseline, 6, and 12 months after first transplantation. In the cell therapy group, Tc 99m Sestamibi (MIBI) single-photon emission computed tomography (SPECT) was performed for measuring myocardial perfusion. In the repeated infusion group, the coronary angiography was done for evaluating in stent restenosis rate (ISR) at 6-months follow-up. All patients received the same or similar medications, including aspirin, clopidogrel, β-blocker, angiotensin converting enzyme inhibitor or angiotensinreceptor blocker, and a statin unless contraindicated. All data and measured values were obtained prospectively.
Patient Population
A total of 45 patients with stable HF and with a large (ST elevation ≥4 limb or precordial leads) recent MI (≤3 months from symptom onset) were enrolled in the phase I clinical study as approved by the ethics committee. Among them, 15 patients who refused cell therapy were assigned to the control group (Group C), 15 patients who were willing to receive repeated cell therapy were assigned to Group R, and the remaining 15 patients were allocated to Group S. Inclusion criteria was symptomatic stable HF with a recent MI and LVEF ≤45%. Exclusion criteria were chronic atrial fibrillation or left bundle-branch block, recent major surgery, known major diseased coronary artery not suitable for cell infusion, apoplexy, malignancies, younger than 18 years or older than 80 years, or any other life-threatening conditions.
PBSC Mobilization, Separation, Collection and Purification
For patients who received the stem cell therapy, an openlabel dose of G-CSF (Lunan Biopharmaceutical Co Ltd) at 10 μg · d -1 · kg -1 of body weight was administered subcutaneously within a 12 h interval for 4-6 days. The group C did not receive a placebo. Blood tests (including, blood chemistry, C-reactive protein (CRP), troponin I, and creatine kinase -MB (CK-MB)), electrocardiogram (ECG), and clinical review were performed before and after PBSC mobilization. Full blood counts were monitored daily and mononuclear cell CD34+ (MNCCD34+) counts were evaluated by flow cytometry (Becton Dickinson) with anti-CD34+ antibodies (Beckman Couter Biotechnology Inc) MNCCD34+ per μl was derived from the relation of CD34+ cells and white blood cells in the blood sample. The optimal time for apheresis was established based on the MNCCD34+ ratio in peripheral blood mononuclear cells. Circulating mononuclear cells were collected using a blood cell separator (Baxter Fanwal Inc). A total of 4,000 to 10,000 ml blood was processed according to practical required volume. The cytopheresis product was centrifuged using the cell processor to deplete blood platelets. Mononuclear cells were washed 3 times with phosphate-buffered saline, then measured and adjusted to a final concentration of 7-9×10 4 CD34+ cells/ml in a flow cytometry (Figure 1) . The a single infusion dose of mononuclear cells was 1.5 to 2×10 8 to guarantee the minimum dose of 1×10 6 CD34 + cells per patient. Bacterial and fungal cultures of the cell preparations were performed and found negative. The number of surviving cells as assessed by trypan blue staining was more than 95%. Time interval between harvest of stem cells and injection was less than 3 h. The number of the infusion cells in therapy groups was similar. Group R patients had their surplus cell suspension kept in freezing medium at -80°C for use in the next transplantation.
Intracoronary Infusion of PBSC
To obtain sufficient coronary blood flow at the infarct-related region, The DES stent was implanted into the infarct-related coronary artery (IRA). Patients were considered not qualified for the protocol if the IRA could not be passed through. An over-the-wire balloon catheter (Maverick, Boston Scientific) was placed at the proximal, middle, and distal end of the IRA. PBSC suspension was injected into the IRA through central lumen of the balloon catheter. The injected volume at each position of the IRA was approximately 5 ml for a total of 15-20 ml per patient. Intracoronary doses of PBSC for the cell therapy groups were similar. There was no intracoronary placebo infusion applied to the control group. A balloon inflation, stop-flow technique was not used for injecting the cell suspension. In addition, we performed a contrast medium backflow study to assess whether the cell suspension reflux from the IRA. All angiography images were digitally stored for offline analysis. ECG and routine blood examinations were performed the day after the procedure. Repeated injection of PBSC was conducted 6 months later after patients received the first cell therapy under a similar procedure and dose of cells. In brief, the frozen monocytes were thawed in the 37°C water. The samples were taken for phenotyping, microbiology testing and living cell assessment. The number of survival cells assessed by trypan blue staining was more than 90%. The remaining steps of the intracoronary infusion were performed as previously described.
Clinical evaluation for the 3 groups included history and physical examination, G-CSF-related complaints, laboratory , and 12 months. Patients were followed by out-patient clinic and telephone. All of patients underwent the above-mentioned evaluations before and after the procedure. In the repeated cell therapy group, CAG evaluated restenosis rate at month 6 follow-up. All images were stored for offline analysis. ISR was defined as a diameter of stenosis >50% within the stented segments including 5-mm segments from stent margin on CAG. All studies were processed and evaluated by experienced operators who were blinded to the assigned therapy.
Assessment of Cardiac Function and Myocardial Perfusion
The echocardiography was performed by a single senior technician. LVEF, LVED, LVFS and other parameters were obtained according to standard protocols. Images were digitally stored and the offline analysis was conducted by a senior reader.
If there was an obvious discrepancy, it would be assessed by a third observer. The rest MIBI SPECT (GE Hawkeye Millennium VG5, USA) was performed for measuring myocardial perfusion at baseline and at follow-up. Studies were assessed by experienced observers blinded to all patient data. For MIBI SPECT, patients received 300 MBq MIBI IV, and resting tomography was performed >30 min later. SPECT involved a Butterworth cut-off frequency of 0.45, with an order of 5 and the reconstructed data created along 3 oblique-axis planes (short axis, vertical long axis and horizontal long axis) of the heart. Quantitative analysis involved use of Cedars quantitative perfusion SPECT. Perfusion defects were calculated by a scintigraphic "bulls-eye" technique.
Statistical Analysis
Continuous variables were expressed as the mean ± standard deviations (mean ± SD). SPSS 16.0 software was used for statistical analysis. Comparisons among groups were performed by one-way analysis of variance (ANOVA) and least-significant difference contrast. A value of P<0.05 was considered statistically significant.
Results
Baseline Clinical Characteristics of Patients
Among 45 patients enrolled in this study 42 patients completed the protocol. The remaining 3 patients were within Group R who did not complete the stem cell therapy: 2 patients had IRA that could not be crossed; 1 patient was withdrawn due to an accelerating ventricular rhythm after apheresis. The baseline characteristics of all the remaining 42 eligible patients were summarized and well matched in Figure 2 . At month 12, SPECT shows that there was significant difference in quantification of perfusion defect change in Group R and Group S, compared with Group C (P<0.001 and P=0.006). At month 12, the reduced myocardial perfusion in Group R was more obvious than that in Group S (P=0.034). Representative rest images of Group R and quantitative myocardial perfusion defect changes assessed by SPECT at baseline and at 6, 12 months are shown in Figure 3 . Accordingly, a significant change in NYHA classification and 6-min walking distance were observed in all 3 groups at Table 2) .
Safety Evaluation
There were no major peri-procedural complications. Two patients in Group R had 3 transient episodes of angina (lasting for 3-9 min) with TIMI blood flow slowdown and ST depression during PBSC infusion. The blood flow and ST segment soon returned to normal levels with relieved angina while the coronary artery being washed with heparin water and reinsertion of the balloon catheter being into the distal end of target coronary artery. During G-CSF administration, 4 patients complained of some symptoms: bone pain (n=2), headache (n=1) and dizziness (n=1). The concentrations of CRP indicating inflammatory response at baseline among the 3 groups showed no significant difference (all P>0.05). CRP was not significantly different from the peri-procedural period and follow-up (all P>0.05). Following daily subcutaneous G-CSF for 5-6 days, a ratio of CD34+ cells from peripheral blood measured by flow cytometry in the cell therapy group rose but there was no significant difference between cell therapy groups (P>0.05) (Figure 1 ). There were no sustained ventricular arrhythmias by ECG monitoring. The number of premature ventricular contractions was similar in the 3 groups. There was a 50% in stent restenosis in IRA of a patient in Group R at 6 months follow up. There were no increases in troponin T or CK-MB indicating myocardial damage during the procedure. Follow-up results demonstrated no re-infarction, apoplexy, tumor or death in the study. Finally, there was no contrast regurgitation observed in any contrast backflow tests (Figure 4 ).
Discussion
The current data provide the first evidence that repeated intracoronary PBSC infusions plus one-time mobilization of GSF in patients with refractory HF following recent MI is a feasible and safe procedure. The two-time PBSC infusions resulted in more striking improvement in cardiac performance during 12-month follow-up than a single PBSC infusion for patients with refractory HF after recent large MI. It also negates the need for bone marrow aspiration and a two-time mobilization of G-CSF by using cryopreserved PBSC for the second injection. Some studies have suggested that G-CSF with and without intracoronary PBSC delivery might improve heart function and myocardial perfusion in post-MI patients. Interestingly, there is an inverse correlation between the PBSC with the degree of LV dysfunction: the higher the plasma level of PBSC, the better the ventricular function. 13 However, there is still controversy regarding the lack of improvement in cardiac function and relatively few stem cells targeted to the heart. 14, 15 Recently, a meta-analysis across 8 randomized controlled trials 6 suggested that administration of G-CSF alone in patients with acute MI fails to improve heart function. An animal model study demonstrated that majority of cells infused into the coronary artery died 72 h after transplantation. 16 The BOOST study revealed that the increase in LVEF lasts for only 6 months suggesting that a single intracoronary infusion of PBSC will not provide long-term benefit. 17 Similarly, Schots et al concluded in his PBSC intracoronary study that poor clinical effect is likely due to a small number of cells homing to the myocardium after a single intracoronary dose. 18 To overcome these effects, optimal routes and times of cell therapy have been the object of several studies. Perin et al was one of the first groups to demonstrate the safety and efficacy of transendocardial BMS injections by electromechanical mapping in animal and then clinical studies. [19] [20] [21] Their study showed that transendocardial delivery was superior to the intracoronary administration and applicable for patients with severe acute or chronic ischemic heart disease. It now seems evident that clinical efficacy is correlated to the number of cells infused. 10 Steinwender et al showed that the combination of G-CSF therapy and a single large dose transcoronary transplantation of CD34+ cells are associated with a significant increase in global LVEF and regional systolic wall motion after 6 months, but seem to imply a high risk for the development of ISR. 22 In 1 case of our pilot study, a transient episode of syncope and convulsion but no ECG change might be connected with cellular embolism during intracoronary of 1×10 9 /ml mononuclear cell infusion. It is conceivable that repeated cell transplantation will be necessary for effective cell therapy. Our preliminary study results reinforce this concept. At 12 months, the 8.9% mean improvement of LVEF in Group R was higher than 5.6% in Group S and 1.6% in Group C. In particular, the 4.5% mean improvement of LVEF from month 6 to month 12 follow up in Group R was more significant than the 1.6% in Group S and 1.0% in Group C. Similarly, the improvement of myocardial perfusion in Group R at 12 months was more than that in Group S and Group C. Interestingly, none of the 12 Group R patients required angioplasty during secondary infusion. These results suggest that repeated intracoronary infusion of PBSC might accelerate LV recovery and induce a larger and continuous improvement compared to a single infusion. It might especially benefit those patients that have not fully recovered after their first cell treatment and might result in a better LVEF improvement Figure 4 . Test of contrast medium flow-back. Representative digital subtraction angiography in a patient showed that contrast medium infused into the coronary artery through Foley's over-the-wire catheter did not flow back to the proximal end of the coronary artery when the sacculus had not been dilated. Green arrow shows no reflux of contrast medium in the proximal balloon. Red arrow appears the flow of contrast agent in its distal. GU X et al.
following the second cell infusion.
Recent clinical data, in accordance with our study, described that a repeated intracoronary BMC transplantation 3 months after the first infusion in patients with a large AMI can significantly improve cardiac function, exercise capacity, and reduce infarct size with beneficial clinical effects lasting for at least 12 months. 23 Another non-randomized clinical study demonstrated no change in LVEF by dobutamine contrast echocardiogram after repeated intracoronary BMC treatment in patients with chronic ischemic HF, but it was associated with the improvement of LV filling and subjective clinical symptom. 24, 25 The discrepancies among these studies might be explained by different doses, timing, the type of MI, and duration of intracoronary infusions, and etc.
It is likely that homing signals might be more intense in acute and subacute MI. Additionally, some clinical studies have showed the effects of autologous BMC transplantation after MI usually might last for more than 6 months. Taking all of these into account, we chose recent AMI (less than 3 months) as the inclusion criteria for the first cell infusion and 6 months after the first transplantation as the secondary cells infusion time. Moreover, to reduce the complication of the related to intervention procedure, we simultaneously performed the PCI to IRA and the first PBSC infusion. However, inconsistent with some other studies, we did not use a balloon inflation stop-flow technique to injecting the cells. Several reasons were considered when using continuous intracoronary cell infusion without balloon inflation in our study. First of all, the initial compensation of failed heart in our enrolled patients with refractory HF after a large recent MI is very poor. The balloon inflation stop-flow could create further ischemia and even induce acute coronary syndrome. Secondly, it is plausible that such a ropiness suspension, fine central lumens and forward flow scarcely could lead to the regurgitation of cells suspension. We at least might corroborate little possibility of cell suspension refluxing by the injecting contrast test. As prescribed previously, Gao et al 26 indicated that there were no significant differences regarding clinical effect between the 2 groups using or not sacculus occlusion. So far, it is still not sure whether such a temporary balloon occlusion might trigger the homing of injected stem cells to the target myocardium.
Our study can only conclude that the repeated administration of PBSC therapy is safe. We did not observe any death, re-infarction, re-vascularization, or tumorigeneses. The frequency and duration of hospitalization in Group R was significantly reduced which might be associated with an improvement of heart function and myocardial perfusion. Indeed, both the dose of diuretics and the number of patients using diuretics were significantly reduced in Group R at 12-month follow up. We observed 2 patients with 3 episodes of transient myocardium ischemia while infusing PBSC in Group R which might be attributed to microemboli following intracoronary infusion 27 according to CAG images. Very recently, bone marrow-derived very small embryonic-like stem cells might have significant implications for cardiac repair after MI. Because its diameter (<6 μm) is too small to cause microvascular occlusion, this kind of cells appear to be suitable for intracoronary delivery. 28 There was no acceleration of ISR in Group R at 6 months. No further increase in serum troponin, CK-MB, and CRP concentrations was observed which suggests that repeated intracoronary PBSC infusion does not significantly induce severe ischemic damage to the myocardium or induce a systemic inflammatory reaction. Current published animal and clinical studies have proved the safety of the repeated intracoronary MSC injections. 11,23,25,29 In addition, safe and feasible repeated endomyocardial injections of cryopreserved MSC injections in Yorkshire swine has been demonstrated. 29 Our study has several limitations: This is a phase I clinical study. The data are still preliminary as each study group has only 15 patients, which might not be sufficient to make a full conclusion on the functional improvement. Furthermore, this study is not randomized and the baseline demographics shown in this study seemed similar among 3 groups. Nonetheless, our data warrents a phase-II, large scale study taking place in a randomized, double blinded, and placebo controlled manner. There is a clear need to further assess the value of repeated intracoronary PBSC infusions in patients with recent MI, preferably with clinical endpoints such as mortality, morbidity, and target vessel revascularization.
In summary, the current clinical study demonstrates that the dual stem cell injection in combination with growth factor injection is a feasible and safe procedure. The repeated stem cell treatment might be potentially beneficial to patients with refractory HF after a recent large MI. Compared to the single dose PBSC infusion, repeated delivery of PBSC plus G-CSF show a better therapeutic potential. The strategy documented in this study offers an option for using celluar therapy with growth factor to better improve post-infarct cardiac function, exercise capacity, and myocardial perfusion.
